Nanomedicine applies nanoscale materials and devices to diagnose, treat and prevent disease with high precision. Many approaches focus on designing nanoparticles that can carry drugs directly to diseased cells while sparing healthy tissue. Typical carriers include liposomes, polymeric nanoparticles, dendrimers, metal and metal oxide nanoparticles, and carbon based nanomaterials such as nanotubes and graphene derivatives. Their surfaces can be engineered with targeting molecules like antibodies or peptides so they recognize specific receptors overexpressed in tumors or inflamed tissues.

In cancer therapy, nanomedicine aims to overcome limitations of conventional chemotherapy, such as systemic toxicity and multidrug resistance. Nanoscale delivery systems can improve solubility of poorly water soluble drugs, extend circulation time, and produce controlled or stimuli responsive release. For example, some nanoparticles are designed to respond to pH, temperature, enzymes or external fields, releasing their cargo preferentially in the tumor microenvironment. Others combine therapy and imaging in a single platform, enabling real time tracking of where the treatment goes.

Diagnostic nanomedicine uses contrast enhancing nanoparticles for imaging techniques such as MRI, CT, optical imaging and ultrasound. These can improve sensitivity for early detection of disease and allow monitoring of treatment response. There is also growing interest in nanosensors that detect biomarkers in blood or other fluids at very low concentrations.

Key challenges include toxicity, immune reactions, long term fate in the body, large scale manufacturing, and regulatory approval. Research is moving from proof of concept studies toward clinically relevant designs, with an emphasis on biocompatibility, reproducibility and clear therapeutic benefit over existing treatments.